Multicomponent meningococcal serogroup B vaccination elicits cross-reactive immunity in infants against genetically diverse serogroup C, W and Y invasive disease isolates
| Autor: | Ana Paula Silva de Lemos, Stefania Bambini, Mariagrazia Pizza, Eva Hong, Sonia Budroni, Ray Borrow, Gabriella De Angelis, Ulrich Vogel, Maria Cecília Gorla, Philip Boucher, Rino Rappuoli, Maria Giuliani, Marzia Monica Giuliani, Sara Tomei, Maurizio Comanducci, Muhamed-Kheir Taha, Jay Lucidarme, Brunella Brunelli, Monica Moschioni, Heike Claus, Alessia Biolchi |
|---|---|
| Přispěvatelé: | GlaxoSmithKline [Siena, Italy] (GSK), Manchester Royal Infirmary, University of Manchester [Manchester], University of Würzburg, Adolfo Lutz Institute [Sao Paulo], Infections Bactériennes Invasives - Invasive Bacterial Infections, Institut Pasteur [Paris], PRA Health Sciences [Fort Washington, PA, USA], This study was sponsored by Novartis Vaccines and Diagnostics, Inc., now part of the GSK group of companies. GlaxoSmithKline Biologicals SA took responsibility for all costs associated with the development and publishing of the present manuscript. The German NRL is supported by the Robert Koch-Institute with funds from the Federal Ministry of Health (funding code 1369-237)., Institut Pasteur [Paris] (IP) |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
Vaccine coverage
sequence type 4CMenB [SDV]Life Sciences [q-bio] multilocus sequence typing Neisseria meningitidis Serogroup B outer membrane vesicle Active immunization MESH: Meningococcal Infections rLP2086 MESH: Meningococcal Vaccines Meningococcal vaccine Serum Bactericidal Antibody Assay 0302 clinical medicine IMD MESH: England Germany Neisseria adhesin A Genotype 030212 general & internal medicine biology Vaccination Non-MenB strains Meningococcal Antigen Typing System Men OMV MESH: Infant 3. Good health ST 4CMenB Meningococcal vaccine Non-MenB strains Cross-protection Serum bactericidal antibody activity Vaccine coverage list: 4CMenB Infectious Diseases England Molecular Medicine France Antibody Cross-protection Brazil MLST 030231 tropical medicine Meningococcal Vaccines serum bactericidal antibody assay using human complement Serogroup factor H binding protein CFU SBA NadA PorA four-component meningococcal serogroup B vaccine 03 medical and health sciences Antigen Immunity MESH: Neisseria meningitidis Serogroup B Humans MESH: Wales serum bactericidal antibody porin A MESH: Germany Antigens Bacterial Wales US MESH: Humans General Veterinary General Immunology and Microbiology Neisserial heparin binding antigen invasive meningococcal disease Public Health Environmental and Occupational Health Serum bactericidal antibody activity Infant meningococcal serogroup MATS MESH: Serogroup MESH: Vaccination Virology United States Meningococcal Infections MESH: France hSBA NHBA biology.protein bivalent factor H binding protein vaccine fHbp colony forming units MESH: Brazil MESH: Antigens Bacterial |
| Zdroj: | Vaccine Vaccine, Elsevier, 2020, 38 (47), pp.7542-7550. ⟨10.1016/j.vaccine.2020.09.050⟩ Vaccine, 2020, 38 (47), pp.7542-7550. ⟨10.1016/j.vaccine.2020.09.050⟩ |
| ISSN: | 0264-410X |
| DOI: | 10.1016/j.vaccine.2020.09.050⟩ |
| Popis: | International audience; Background: The multicomponent meningococcal serogroup B vaccine (4CMenB) is currently indicated for active immunization against invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB). However, genes encoding the 4CMenB antigens are also variably present and expressed in strains belonging to other meningococcal serogroups. In this study, we evaluated the ability of antibodies raised by 4CMenB immunisation to induce complement-mediated bactericidal killing of non-MenB strains. Methods: A total of 227 invasive non-MenB disease isolates were collected between 1 July 2007 and 30 June 2008 from England and Wales, France, and Germany; 41 isolates were collected during 2012 from Brazil. The isolates were subjected to genotypic analyses. A subset of 147 isolates (MenC, MenW and MenY) representative of the meningococcal genetic diversity of the total sample were tested in the human complement serum bactericidal antibody assay (hSBA) using sera from infants immunised with 4CMenB. Results: Serogroup and clonal complex repertoires of non-MenB isolates were different for each country. For the European panel, MenC, MenW and MenY isolates belonged mainly to ST-11, ST-22 and ST-23 complexes, respectively. For the Brazilian panel, most MenC and MenW isolates belonged to the ST-103 and ST-11 complexes, respectively, and most MenY isolates were not assigned to clonal complexes. Of the 147 non-MenB isolates, 109 were killed in hSBA, resulting in an overall coverage of 74%. Conclusion: This is the first study in which 147 non-MenB serogroup isolates have been analysed in hSBA to evaluate the potential of a MenB vaccine to cover strains belonging to other serogroups. These data demonstrate that antibodies raised by 4CMenB are able to induce bactericidal killing of 109 non-MenB isolates, representative of non-MenB genetic and geographic diversity. These findings support previous evidence that 4CMenB immunisation can provide cross-protection against non-MenB strains in infants, which represents an added benefit of 4CMenB vaccination. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect